These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 717578)

  • 1. Sexual function and affect in parkinsonian men treated with L-dopa.
    Brown E; Brown GM; Kofman O; Quarrington B
    Am J Psychiatry; 1978 Dec; 135(12):1552-5. PubMed ID: 717578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial cognitive profiles in levodopa-induced hypersexuality.
    Harvey NS
    Br J Psychiatry; 1988 Dec; 153():833-6. PubMed ID: 3256388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced luteinizing hormone secretion in women with Parkinson's disease.
    Bonuccelli U; Piccini P; Napolitano A; Cagnacci A; Paoletti AM; Melis GB; Muratorio A
    J Neural Transm Park Dis Dement Sect; 1990; 2(3):225-31. PubMed ID: 2257062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
    Shif M; Kempster PA
    Clin Exp Neurol; 1994; 31():38-42. PubMed ID: 7586663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypersexuality--a complication of dopaminergic therapy in Parkinson's disease.
    Vogel HP; Schiffter R
    Pharmacopsychiatria; 1983 Jul; 16(4):107-10. PubMed ID: 6685318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson's disease.
    Witt K; Daniels C; Herzog J; Lorenz D; Volkmann J; Reiff J; Mehdorn M; Deuschl G; Krack P
    J Neuropsychiatry Clin Neurosci; 2006; 18(3):397-401. PubMed ID: 16963590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sexual delinquency and Parkinson's disease].
    Berger Ch; Mehrhoff FW; Beier KM; Meinck HM
    Nervenarzt; 2003 Apr; 74(4):370-5. PubMed ID: 12707708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Patients with Parkinson disease: functional analysis of dopamine receptors by bromocriptine- thyrotropin-releasing hormone test].
    Díaz F; Liberman C; Chariá P
    Rev Med Chil; 1991 Mar; 119(3):252-7. PubMed ID: 1842116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK; Verma S; Cordingley GJ; Harris RI
    Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.
    Meco G; Bernardi S
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):311-3. PubMed ID: 16919377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results of short and long-term treatment of parkinsonism with L-dopa].
    Domzal T; Pakszys W; Domzal B; Ligezińska B
    Neurol Neurochir Pol; 1976; 10(5):637-43. PubMed ID: 980203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease. The L-dopa era.
    Yahr MD
    Adv Neurol; 1993; 60():11-7. PubMed ID: 8420128
    [No Abstract]   [Full Text] [Related]  

  • 20. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.